JAK3突变与T细胞急性淋巴细胞白血病线粒体凋亡抵抗
该研究通过对儿童T-ALL临床标本进行BH3 profiling和外显子测序,发现线粒体凋亡抵抗与JAK3激活突变最强相关;JAK3突变直接抑制白血病细胞凋亡,JAK3抑制剂可逆转线粒体凋亡阻断,且JAK3突变原代样本依赖BCL2;托法替尼与糖皮质激素在体外和体内均显示协同作用。
要点
- 儿童T-ALL中,线粒体凋亡抵抗与JAK3激活突变最强相关。
- JAK3突变直接抑制凋亡,JAK3抑制剂可逆转线粒体凋亡阻断。
- JAK3突变原代T-ALL样本依赖BCL2,托法替尼与糖皮质激素协同。
核心结论
- JAK3激活突变与儿童T-ALL线粒体凋亡抵抗最强相关,JAK3抑制剂联合糖皮质激素可为JAK3突变T-ALL患者临床试验提供依据。
研究设计与样本
- 研究对儿童T-ALL临床标本进行BH3 profiling和外显子测序分析。
主要发现
- 线粒体凋亡抵抗与JAK3激活突变最强相关。
- JAK3突变直接抑制白血病细胞凋亡,机制不同的JAK3药理学抑制剂均可逆转线粒体凋亡阻断。
- JAK3抑制导致MEK、ERK和BCL2磷酸化丢失。
- BH3 profiling显示JAK3突变原代T-ALL患者样本依赖BCL2。
- 托法替尼与糖皮质激素在体外和体内均显示协同作用。
临床怎么用
- 作者认为,JAK3突变T-ALL患者可考虑JAK3抑制剂联合糖皮质激素的临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to mitochondrial apoptosis predicts inferior treatment outcomes in patients with diverse tumor types, including T-cell acute lymphoblastic leukemia (T-ALL). However, the genetic basis for variability in this mitochondrial apoptotic phenotype is poorly understood, preventing its rational therapeutic targeting. Using BH3 profiling and exon sequencing analysis of childhood T-ALL clinical specimens, we found that mitochondrial apoptosis resistance was most strongly associated with activating mutations of JAK3. Mutant JAK3 directly repressed apoptosis in leukemia cells, because its inhibition with mechanistically distinct pharmacologic inhibitors resulted in reversal of mitochondrial apoptotic blockade. Inhibition of JAK3 led to loss of MEK, ERK and BCL2 phosphorylation, and BH3 profiling revealed that JAK3-mutant primary T-ALL patient samples were characterized by a dependence on BCL2. Treatment of JAK3-mutant T-ALL cells with the JAK3 inhibitor tofacitinib in combination with a spectrum of conventional chemotherapeutics revealed synergy with glucocorticoids, in vitro and in vivo. These findings thus provide key insights into the molecular genetics of mitochondrial apoptosis resistance in childhood T-ALL, and a compelling rationale for a clinical trial of JAK3 inhibitors in combination with glucocorticoids for patients with JAK3-mutant T-ALL.
引用
- Bodaar K, Yamagata N, Barthe A, et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022. PMID: 35411095. doi:10.1038/s41375-022-01558-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。